Conatus Pharmaceuticals Inc. (CNAT)

3.70
NASDAQ : Health Technology
Prev Close 3.67
Day Low/High 3.63 / 3.80
52 Wk Low/High 3.22 / 7.95
Avg Volume 700.60K
Exchange NASDAQ
Shares Outstanding 30.06M
Market Cap 110.33M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACIW, AMC, CTRP, GSIT, ITGR, JNP, KFFB, MD, MDSO, NJR, VECO Downgrades: NEM, TFX, TTEC Initiations: CNAT, OTEL Read on to get TheStreet Quant Ratings' detailed report:

Commit To Buy Conatus Pharmaceuticals At $2.50, Earn 9.4% Annualized Using Options

Commit To Buy Conatus Pharmaceuticals At $2.50, Earn 9.4% Annualized Using Options

Investors eyeing a purchase of Conatus Pharmaceuticals Inc stock, but cautious about paying the going market price of $4.07/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2018 put at the $2.50 strike, which has a bid at the time of this writing of 10 cents.

Short Interest Decreases By 30.6% For CNAT

Short Interest Decreases By 30.6% For CNAT

The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 642,982 share decrease in total short interest for Conatus Pharmaceuticals Inc , to 1,461,190, a decrease of 30.56% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Oversold Conditions For Conatus Pharmaceuticals (CNAT)

Oversold Conditions For Conatus Pharmaceuticals (CNAT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Conatus Pharmaceuticals Announces Poster Presentation At AASLD Annual Meeting

Conatus Pharmaceuticals Announces Poster Presentation At AASLD Annual Meeting

Pan-caspase Inhibitor IDN-7314 Reduces Liver Injury Due to Intestinal Bacteria Imbalance Resulting from Restricted Bile Flow in Mouse Model of PSC

Conatus Pharmaceuticals Announces Poster Presentation At International Liver Cell Conference

Emricasan Improves and Sustains Key Functions in Cirrhotic Liver Cells

Fewer Oars Make Market Tough Row to Hoe

Fewer Oars Make Market Tough Row to Hoe

Investors should be more cautious heading into the summer.

TheStreet Quant Rating: D (Sell)